abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeblueskyburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfilterflaggenderglobeglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptriangletwitteruniversalitywebwhatsappxIcons / Social / YouTube

Эта страница недоступна на Русский и отображается на English

Статья

16 Фев 2009

Автор:
Michelle Childs, Director of Policy and Advocacy, Campaign for Access to Essential Medicines, Médecins Sans Frontières

MSF response to GSK patent pool proposal

Médecins Sans Frontières welcomes Mr. Witty’s recognition that patents act as a barrier to research and development and that patent pools offer new ways to stimulate research into neglected diseases. Promises now need to be turned into action... MSF calls on all other pharmaceutical companies to lift patent barriers…But GSK must extend this thinking to include HIV: HIV is also a neglected disease. Mr. Witty claims that a patent pool is meant to focus on diseases with a severe lack of treatments and that there is sufficient innovation for HIV. He is wrong.